Summary
Cencora, Inc. reported a strong first quarter for fiscal year 2025, demonstrating robust revenue growth driven by its U.S. Healthcare Solutions segment. Total revenue for the quarter increased by 10.3% year-over-year, reaching $75.5 billion, with the U.S. segment experiencing a significant 11.4% rise. This growth was bolstered by strong unit volume increases, notably a 36.1% surge in sales of GLP-1 class drugs for diabetes and weight loss, totaling $2.2 billion. Net income attributable to Cencora, Inc. rose to $717.9 million, a substantial increase from $420.8 million in the prior year's first quarter, translating to diluted earnings per share of $3.68. The company also benefited from a substantial gain related to antitrust litigation settlements, contributing significantly to the increase in gross profit. Despite increased operating expenses, largely due to the recent acquisition of Retina Consultants of America (RCA) and associated integration costs, the company managed to expand its operating income by 87.3% year-over-year to $1,036.2 million. Cencora also highlighted continued capital allocation through share repurchases and dividend payments.
Financial Highlights
55 data points| Revenue | $75.45B |
| Cost of Revenue | $72.39B |
| Gross Profit | $3.06B |
| SG&A Expenses | $1.60B |
| Operating Income | $1.04B |
| Net Income | $717.87M |
| EPS (Basic) | $3.70 |
| EPS (Diluted) | $3.68 |
| Shares Outstanding (Basic) | 193.80M |
| Shares Outstanding (Diluted) | 195.09M |
Key Highlights
- 1Revenue increased by 10.3% to $75.5 billion in Q1 FY25, driven by the U.S. Healthcare Solutions segment which saw an 11.4% rise.
- 2Sales of GLP-1 class drugs for diabetes and weight loss grew by 36.1% ($2.2 billion) year-over-year, a key driver of revenue.
- 3Net income attributable to Cencora, Inc. significantly increased to $717.9 million from $420.8 million in Q1 FY24.
- 4Diluted earnings per share improved to $3.68, up from $2.09 in the prior year's comparable quarter.
- 5Gross profit saw a substantial increase of 20.6% to $3.1 billion, boosted by higher sales and significant gains from antitrust litigation settlements.
- 6Operating income grew by a strong 87.3% to $1.04 billion, reflecting improved operational efficiency and revenue growth, despite higher operating expenses.
- 7The company completed the acquisition of Retina Consultants of America (RCA) in January 2025, contributing to increased goodwill and integration expenses.